ClinicalTrials.Veeva

Menu
A

Adelaide Eye and Retina Centre | Adelaide, South Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KHK4951
BI 765128
Lampalizumab
Dexamethasone
Faricimab
EXN407
Aflibercept
JNJ-81201887
IBE-814

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 12 total trials

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (CONSTANCE)

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of int...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Drug: Faricimab

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Enrolling
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

Trial sponsors

Roche logo
Kyowa Kirin logo
Bayer logo
Boehringer Ingelheim logo
E
Genentech logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems